GATA2 deficiency significantly elevates the lifetime risk of developing MDS, with an enhanced likelihood of progressing to AML (35). It is recognized as the predominant hereditary cause of MDS in adolescents with monosomy 7 (35). Furthermore, compared to wild-type cases, GATA2 mutant MDS is associated with lower survival and faster disease progression (7). This evidence concerns the gene GATA2 and myelodysplastic syndrome.